### Vinblastine

**Essential medicine status**

**ATC codes:** L01CA01

### Indication
Anaplastic large cell lymphoma, ALK-positive

**ICD11 code:** 2A90.A

### INN
Vinblastine

### Medicine type
Chemical agent

### List type
Complementary

### Additional notes
For intravenous use only

### Formulations
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

### EML status history
First added in 2023 (TRS 1049)

### Sex
All

### Age
Also recommended for children

### Therapeutic alternatives
The recommendation is for this specific medicine

### Patent information
Patents have expired in most jurisdictions

**Read more about patents.**

### Tags
- Cancer

### Wikipedia
Vinblastine

### DrugBank
Vinblastine

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the current listings of cyclophosphamide, cytarabine, dexamethasone, doxorubicin, etoposide, ifosfamide, methotrexate, prednisolone and vinblastine on the complementary list of the EML and EMLc be extended to include the new indication of anaplastic large cell lymphoma (ALCL). These medicines are recognized as part of the standard of care for ALCL. Their benefits and harms were accepted as being well established from use in other indications in children and in adults.